Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 1,654

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Open access
Scher, Howard I., Morris, Michael J., Stadler, Walter M., Higano, Celestia, Basch, Ethan, Fizazi, Karim, Antonarakis, Emmanuel S., Beer, Tomasz M., Carducci, Michael A., Chi, Kim N., Corn, Paul G., de Bono, Johann S., Dreicer, Robert, George, Daniel J., Heath, Elisabeth I., Hussain, Maha, Kelly, Wm. Kevin, Liu, Glenn, Logothetis, Christopher, Nanus, David, Stein, Mark N., Rathkopf, Dana E., Slovin, Susan F., Ryan, Charles J., Sartor, Oliver, Small, Eric J., Smith, Matthew Raymond, Sternberg, Cora N., Taplin, Mary-Ellen, Wilding, George, Nelson, Peter S., Schwartz, Lawrence H., Halabi, Susan, Kantoff, Philip W., Armstrong, Andrew J. · 2016 · Journal of Clinical Oncology

Abstract

Purpose: Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations to succeed those from prior Prostate Cancer Clinical Trials Working Groups. Methods: An international expert committee of prostate cancer clinical investigators (the Prostate Cancer Clinical Trials Working Group 3 [PCWG3]) was reconvened and expanded and met in 2012-2015 to formulate updated criteria on the basis of emerging trial data and validation studies of the Prostate Cancer Clinical Trials Working Group 2 recommendations. Results: PCWG3 recommends that baseline patient assessment include tumor histology, detailed records of prior systemic treatments and responses, and a detailed reporting of disease subtypes based on an anatomic pattern of metastatic spread. New recommendations for trial outcome measures include the time to event end point of symptomatic skeletal events, as well as time to first metastasis and time to progression for trials in the nonmetastatic CRPC state. PCWG3 introduces the concept of no longer clinically benefiting to underscore the distinction between first evidence of progression and the clinical need to terminate or change treatment, and the importance of documenting progression in existing lesions as distinct from the development of new lesions. Serial biologic profiling using tumor samples from biopsies, blood-based diagnostics, and/or imaging is also recommended to gain insight into mechanisms of resistance and to identify predictive biomarkers of sensitivity for use in prospective trials. Conclusion: PCWG3 moves drug development closer to unmet needs in clinical practice by focusing on disease manifestations most likely to affect prognosis adversely for therapeutics tested in both nonmetastatic and metastatic CRPC populations. Consultation with regulatory authorities is recommended if a trial is intended to seek support for drug approval.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.64.2702

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 1,654

Metadata

Authors
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., Corn, P. G., de Bono, J. S., Dreicer, R., George, D. J., Heath, E. I., Hussain, M., Kelly, W. K., Liu, G., Logothetis, C., Nanus, D., Stein, M. N., Rathkopf, D. E., Slovin, S. F., Ryan, C. J., Sartor, O., Small, E. J., Smith, M. R., Sternberg, C. N., Taplin, M.-E., Wilding, G., Nelson, P. S., Schwartz, L. H., Halabi, S., Kantoff, P. W., & Armstrong, A. J.
Venue
Journal of Clinical Oncology
Published
2016-04-20
Volume
34
Issue
12
Pages
1402-1418
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2278392405
Cited by
1,654
References
63
FWCI
97.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.